ArticleBioinformation2025
Adverse drug reaction reporting and monitoring: A review of global practices.
Article in Bioinformation, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The negative drug reactions (ADRs) are a major challenge to the global health due to their contribution to morbidity and mortality as well as the increased healthcare expenditure. Therefore, it is of interest to explore the international contextual situation of ADR reporting and monitoring systems, their development, their presence in the market, and their future perspectives. The review provides an overview of different pharmacovigilance frameworks put in place by international organizations and national regulatory bodies and their weaknesses and strengths. It was found that despite the tremendous progress achieved in the formation of global pharmacovigilance networks, much still needs to be done in the detection, reporting, and prevention of ADRs especially in the low and middle-income countries. The review identifies new trends and possible innovations that can change ADR monitoring in the decade and provide patient- centered reporting, integrate real-world evidence, and predictive toxicology methods.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.